中文版正在生成中，先为你展示英文版分析。
AI核心结论
IQVIA (IQV) delivered 5.9% revenue growth to $16.31B in FY2025, but operating income and net income each declined ~0.9% as rising costs compressed operating margin from 14.3% to 13.4%, while EPS rose 4.5% to $7.91 on share buybacks.
营业收入
$16.31B
同比 ++5.87%
每股收益（基本）
$7.91
同比 ++4.49%
营业利润
$2.18B
同比 -0.91%
提交于 · 解读更新于 · 来源: SEC EDGAR 10-K 原文
Iqvia Holdings (IQV) FY2025 营收 $16.31B，同比增长 5.9%。 净利润 $1.36B，同比下降 0.9%，稀释每股收益 $7.84。
IQV grew total revenue by 5.9% year-over-year to $16.31B in FY2025 (from $15.41B in the prior year), reflecting continued demand for its contract research, technology, and data analytics services across the life sciences sector.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Operating margin declined from 14.3% to 13.4% year-over-year, with operating income falling slightly to $2.18B from $2.20B, suggesting that cost growth outpaced revenue expansion. SG&A expenses remained elevated at $2.00B, up 0.4% YoY.
来源: Source: 10-K Income Statement & Key Ratios (XBRL Financial Data)
Despite flat-to-declining net income ($1.36B vs. $1.37B prior year), basic EPS rose 4.5% to $7.91 and diluted EPS rose 4.7% to $7.84, primarily because share buybacks of $1.24B reduced the share count, boosting per-share earnings.
来源: Source: 10-K Income Statement & Cash Flow Statement (XBRL Financial Data)
Investing cash outflows surged 59.6% to -$2.31B, indicating substantial capital deployment (likely acquisitions or capex), while long-term debt rose 8.1% to $13.88B, increasing financial leverage. Total assets grew 11.3% to $29.94B.
来源: Source: 10-K Balance Sheet & Cash Flow Statement (XBRL Financial Data)
Operating cash flow was $2.65B in FY2025, down 2.3% from $2.72B in the prior year, reflecting the modest pressure on earnings and working capital, though cash generation remains robust relative to net income.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
IQV carries $13.88B in long-term debt with a debt-to-equity ratio of 3.59x, which is elevated. The 8.1% increase in long-term debt in FY2025 raises refinancing and interest cost risks, particularly in a higher-for-longer interest rate environment.
来源: Source: 10-K Balance Sheet (XBRL Financial Data)
IQV's current ratio stands at only 0.75x, meaning current liabilities of $8.34B significantly exceed current assets of $6.25B. Current liabilities surged 19.9% YoY, which could strain short-term liquidity if cash flows weaken.
来源: Source: 10-K Balance Sheet & Key Ratios (XBRL Financial Data)
Operating margin contracted by approximately 90 basis points to 13.4% in FY2025, as cost growth outpaced revenue growth. Sustained margin pressure could reduce profitability even if top-line growth continues.
来源: Source: 10-K Income Statement & Key Ratios (XBRL Financial Data)
Investing cash outflows jumped 59.6% to -$2.31B in FY2025, suggesting significant M&A or capital expenditure activity. Large acquisitions carry integration risk and may not deliver expected returns, potentially weighing on future earnings.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
EPS growth of 4.5%-4.7% in FY2025 was achieved despite flat net income, relying heavily on $1.24B in share repurchases. If free cash flow declines or debt obligations increase, the company's ability to sustain buybacks may be constrained.
来源: Source: 10-K Income Statement & Cash Flow Statement (XBRL Financial Data)
FY2025 实际 EPS $3.42，分析师一致预期 $3.43，不及预期 -0.3%。
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营业收入 | $16.31B | $15.4B | +5.87% |
营业利润 | $2.18B | $2.2B | -0.91% |
净利润 | $1.36B | $1.37B | -0.95% |
每股收益（基本） | $7.91 | $7.57 | +4.49% |
每股收益（稀释） | $7.84 | $7.49 | +4.67% |
销售及管理费用 | $2B | $1.99B | +0.35% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
总资产 | $29.94B | $26.9B | +11.32% |
流动资产 | $6.25B | $5.83B | +7.21% |
总负债 | $23.31B | $20.83B | +11.91% |
流动负债 | $8.34B | $6.96B | +19.85% |
股东权益 | $6.5B | $6.07B | +7.19% |
现金及等价物 | $1.98B | $1.7B | +16.33% |
长期债务 | $13.88B | $12.84B | +8.15% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
经营活动现金流 | $2.65B | $2.72B | -2.28% |
投资活动现金流 | $-2.31B | $-1.44B | -59.63% |
筹资活动现金流 | $-150M | $-878M | +82.92% |
股票回购 | $1.24B | $1.35B | -7.85% |
折旧及摊销 | $1.14B | $1.11B | +2.69% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营业利润率 | 13.4% | 14.3% | -0.92% |
净利率 | 8.3% | — | — |
净资产收益率 | 20.9% | — | — |
总资产收益率 | 4.5% | — | — |
流动比率 | $0.749 | — | — |
资产负债率 | $3.585 | — | — |
Life Sciences Tools & Services 行业其他公司
IQV grew revenue by 5.9% year-over-year to $16.31B in FY2025, up from $15.41B in the prior year. This growth reflects continued demand for the company's contract research, technology solutions, and data analytics services in the life sciences industry.
IQV delivered solid top-line growth of 5.9% to $16.31B, but operating income and net income each declined about 0.9% due to cost pressures that compressed operating margin from 14.3% to 13.4%. EPS still rose 4.5% to $7.91 thanks to $1.24B in share buybacks reducing the share count.
Key financial risks include high leverage with $13.88B in long-term debt and a debt-to-equity ratio of 3.59x, as well as a current ratio of only 0.75x indicating potential short-term liquidity pressure. Additionally, a 59.6% surge in investing outflows to -$2.31B suggests significant capital deployment that carries integration and return-on-investment risk.
IQV is profitable with net income of $1.36B and operating cash flow of $2.65B in FY2025, but its financial health is tempered by high debt ($13.88B long-term debt), a below-1.0 current ratio (0.75x), and declining margins. Investors should watch the company's ability to manage leverage while sustaining cash generation.
Yes, IQV's basic EPS rose 4.5% to $7.91 and diluted EPS rose 4.7% to $7.84 in FY2025, even though net income was essentially flat at $1.36B. The improvement was driven by share repurchases of $1.24B, which reduced the share count and boosted per-share profitability.